Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate (Q42168250)

17 October 2017

Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate (English)

1 reference

17 October 2017

Minna Laitinen

11

0 references

Yrjö Konttinen

7

object named as

Yrjö T Konttinen

1 reference

17 October 2017

Pia Heikkilä

1

1 reference

17 October 2017

Olli Teronen

2

1 reference

17 October 2017

Martti Y Hirn

3

1 reference

17 October 2017

Timo Sorsa

4

1 reference

17 October 2017

Taina Tervahartiala

5

1 reference

17 October 2017

Tuula Salo

6

1 reference

17 October 2017

Tuula Halttunen

8

1 reference

17 October 2017

Merja Moilanen

9

1 reference

17 October 2017

Roeland Hanemaaijer

10

1 reference

17 October 2017

1 May 2003

1 reference

Journal of Surgical Research

17 October 2017

1 reference

17 October 2017

111

1 reference

17 October 2017

1

1 reference

17 October 2017

45-52

1 reference

Matrix metalloproteinases and their inhibitors in tumour growth and invasion

17 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Identification and structural and functional characterization of human enamelysin (MMP-20)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Invasiveness and MMP expression in pancreatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Design and synthesis of thiol containing inhibitors of matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

A chemically modified nonantimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Systemic doxycycline administration in the treatment of periodontal infections (II). Effect on antibiotic resistance of subgingival species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

New bisphosphonates in the treatment of bone metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

A matrix metalloproteinase expressed on the surface of invasive tumour cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Identification and characterization of gelatinases/type IV collagenases in jaw cysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

MMP inhibition and downregulation by bisphosphonates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Type IV collagenases in tumor invasion and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Membrane proteases in focus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Development of matrix metalloproteinase inhibitors in cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Biochemical characterization of human collagenase-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Tumor targeting with a selective gelatinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

CMT-8/clodronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900086-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-4804(03)00086-6

1 reference

17 October 2017

1 reference